Kura Oncology is a biopharmaceutical company that develops precision medicines for cancer treatment by targeting specific molecular mutations in cancer signaling pathways. The company's commercial portfolio includes KOMZIFTI, a selective menin inhibitor for acute myeloid leukemia with NPM1 mutations, along with a pipeline of next-generation menin inhibitors and farnesyl transferase inhibitors for various solid tumors and hematologic malignancies. Kura generates revenue through product sales and partnership arrangements, including a collaboration with Kyowa Kirin under which Kura leads U.S. development and commercialization while receiving a share of profits and milestone payments, and employs a field sales team to reach thousands of oncology accounts and manage payer relationships.